Teva Wins FDA Approval for Once-Monthly Schizophrenia Injection

Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for WELTRUZA (olanzapine), a once-monthly injectable treatment for adults with schizophrenia. The extended-release formulation is the first and only once-monthly subcutaneous olanzapine injection approved in the United States.

The treatment is designed to provide a longer-acting alternative to daily oral olanzapine, an antipsychotic medicine widely used to manage schizophrenia. WELTRUZA is injected under the skin and is expected to be available in the US in three strengths: 318 mg, 425 mg and 531 mg.

According to Teva, the treatment does not require loading doses, additional oral medication or routine monitoring after each injection. These features may help simplify treatment for patients who find it difficult to take daily medication consistently.

The FDA approval is based on results from the Phase 3 SOLARIS clinical trial, which evaluated the safety and effectiveness of WELTRUZA in adults with schizophrenia. The study found improvements in symptoms, a reduction in illness severity and better personal and social functioning among patients receiving the treatment.

The trial also found that the three doses had similar tolerability profiles. The most commonly reported side effects included weight gain, sleepiness, headache, constipation and reactions at the injection site. Weight gain and metabolic changes were consistent with the known safety profile of oral olanzapine.

Teva cautioned that WELTRUZA carries important safety risks associated with olanzapine. These include high blood sugar, metabolic changes, sleepiness and other potentially serious side effects. The medicine is not approved for people with dementia-related psychosis. Although a serious condition called post-injection delirium/sedation syndrome has been reported with another extended-release olanzapine injection, it is not known whether it can occur with WELTRUZA.

“WELTRUZA offers the proven efficacy of olanzapine in an innovative long-acting subcutaneous injectable, helping to fill a major, long-standing gap in the schizophrenia treatment landscape,” said Chris Fox, executive vice president of US commercial operations and head of Teva’s Innovative Franchise.

Eric Hughes, Teva’s executive vice president of global research and development and chief medical officer, said the approval reflects the company’s focus on developing treatments around patients’ needs. He added that removing the need for monitoring after each injection could address an important barrier to treatment.

Schizophrenia is a long-term mental health condition that can affect how a person thinks, feels and behaves. Symptoms may include hallucinations, delusions and difficulties with thinking and daily activities. Consistent treatment is important, but some patients struggle to take oral medication every day, which can increase the risk of symptoms returning.

WELTRUZA uses SteadyTeq, a controlled-release technology developed by French biotechnology company Medincell. The technology is designed to release olanzapine gradually after injection, supporting treatment over a one-month period.

The FDA approval also builds on Teva’s collaboration with Medincell. Their earlier product, Uzedy, a long-acting injectable formulation of risperidone, was approved in the US in 2023.

Teva is also pursuing regulatory approval for its long-acting injectable olanzapine in Europe. The European Medicines Agency accepted the company’s marketing authorisation application in May 2026, although the treatment has not yet been approved in the region.

The approval expands the range of long-acting injectable treatments available for schizophrenia. By offering monthly dosing, Teva aims to provide patients and healthcare professionals with another option for managing the condition while supporting consistent treatment over time.

You might also like